6th Annual MarketsandMarkets

Next-Gen Immuno-Oncology Conference

22nd -23rd June 2023

Hilton Boston Logan Airport

Our 6th Annual MarketsandMarkets Next Gen Immuno-Oncology Conference to be held on 22nd - 23rd June 2023, at Hilton Boston Logan Airport, Boston, would address the challenges and future directions in IO research. The congress aims to bring academicians, researchers and scientists from research institutes pharmaceutical, bio-pharmaceutical and biotechnology companies to discuss the latest updates in development of ADC’s, Bispecific Antibodies, Cellular Therapy and Immune Checkpoint Inhibitors.

This congress would also focus on various combination strategies, pre-clinical and translational immune-oncology developments, updates in cellular and viral therapies, vaccines development and personalized immunotherapy. Keynote presentations, Brainstorming Panel Discussions and Case studies will give the stakeholders an opportunity to discuss and understand the issues faced and come up with solutions. With more than 20 speakers across the world from pharma, bio-pharma and biotech companies, the congress will discuss the latest updates in development of ADC’s, Monoclonal Antibodies, Bispecific Antibodies, Immune Checkpoint Inhibitors and Cellular Therapy

CO-LOCATED CONFERENCES

WHAT TO EXPECT

  • Updates in development of ADC’s and Bispecific Ab’s
  • Immune Checkpoint Inhibitors and Combinations
  • Preclinical and Translational Immuno-Oncology Developments (Preclinical models for Immune checkpoint modulators)
  • Biomarkers and Personalized Medicine in IO
  • CAR-T Cell therapy, TCR Based-Cell Therapy
  • Tumor microenvironment and Oncolytic Viruses

CSO, Director, VP, Head, Senior Investigator, Manager, Principal Scientist, Team Leader, Group Leaders, Professors, Assistant Professors, Research fellows, PhDs working on

  • Monoclonal and Bispecific Antibodies
  • Cell Therapy
  • Immune Checkpoint Inhibitors

  • Exclusive conference to learn about antibodies, cellular therapy and immune-checkpoint research under one roof
  • Find out new case studies of immune-oncology projects in development
  • Contribute to interactive roundtables with your peers to deliberate key topics most relevant to you
  • Explore the latest platforms and technologies on the market for development
  • Discuss the best tool for your research in immune-oncology
  • Share your work and achievements with your industry peers in the Poster Session

CONFERENCE AGENDA

Registration

08:15 - 08:50

Welcome note from MarketsandMarkets

08:50 - 08:55

Opening remarks from the Chairman

08:55 - 09:00

New Antibody Formats & Cellular Therapy

Keynote: Immuno-oncology Continues to Transform Oncology Therapeutics

Roy Baynes

Roy Baynes, Executive Vice President, Chief Medical Officer, Eikon Therapeutics

09:00 - 09:30

Solution Provider Presentation

09:30 - 10:00

Evaluating Efficacy of Novel Antibody and Cell-Based Therapeutics with Next-Generation Mouse Models

Jenna Frame

Jenna Frame, Senior Scientist, Scientific Communications, Biocytogen

10:00 - 10:30

Morning Refreshments and Poster Presentations | One-to-One Networking Meetings

10:30 - 11:15

Challenges and Opportunities for Immuno-oncology (IO) and Antibody Drug Conjugates (ADC) Therapeutics To Treat Cancers

Rakesh Dixit

Rakesh Dixit, CEO, Bionavigen

11:15 - 11:45

Adoptive Cellular Therapy

11:45 - 12:15

Targeting cancer with ADC’s-Case study

12:15 - 12:45

Development of bispecific antibodies for cancer therapy

12:45 - 13:15

Lunch and Poster Presentations | One-to-One Networking Meetings

13:15 - 14:15

Challenges in the nonclinical development of mAb-based cancer immunotherapy

14:15 - 14:45

Search for “right” molecule and “right” dose: Case Studies from immuno-oncology portfolio

Ayse Meric Ovacik

Ayse Meric Ovacik, Senior Principal Scientist, Genentech

14:45 - 15:15

Solution Provider Presentation

15:15 - 15:45

Afternoon Refreshments and Poster Presentations | One-to-One Networking Meetings

15:45 - 16:30

Preclinical safety/toxicity evaluation of next generation CAR-T/TCR-T therapies

Yixiang Xu

Yixiang Xu, Senior Scientist, Bristol Meyers Squibb

16:30 - 17:00

Evaluating clinical and pharmacodynamic data of CLL patients treated with ibrutinib and an ADCC- enhanced anti-BAFF-R antibody (VAY736)

 Nadia Hassounah

Nadia Hassounah, Principal Scientist, Novartis

17:00 - 17:30

Choosing IO in multiple myeloma-Case Study

17:30 - 18:00

Closing remarks from the Chairman

18:00 - 18:00

End of Day 1 followed by Drinks Reception and Networking

18:00 - 18:00

Registration

08:15 - 08:50

Welcome note from MarketsandMarkets

08:50 - 08:55

Opening remarks from the Chairman

08:55 - 09:00

New Immune Checkpoints, Biomarker and Tumour Microenvironment

Keynote:

09:00 - 09:30

Solution Provider Presentation

09:30 - 10:00

Role of Tumour Micro-Enviroment in Oncolytic Viral Therapy

10:00 - 10:30

Morning Refreshments and Poster Presentations | One-to-One Networking Meetings

10:30 - 11:15

Solution Provider Presentation

11:15 - 11:45

New IO Combination therapies and Biomarkers

11:45 - 12:15

Next-generation checkpoints beyond PD-1 and CTLA-4

12:15 - 12:45

Cancer Vaccines and new developments

12:45 - 13:15

Lunch and Poster Presentations | One-to-One Networking Meetings

13:15 - 14:15

Combining oncolytic viruses with immune checkpoint inhibitors

14:15 - 14:45

Solution Provider Presentation

14:45 - 15:15

Immunomodulation in IO

15:15 - 15:45

Closing remarks from the Chairman

15:45 - 15:45

End of Conference

15:45 - 15:45

ENQUIRE NOW

SPEAKERS

Senior Representative Sanyou Bio

Senior Representative Sanyou Bio

, Sanyou Bio

Bradley Heckmann

Bradley Heckmann

Co-Founder, CSO, Asha Therapeutics

Yixiang Xu

Yixiang Xu

Senior Scientist, Bristol Meyers Squibb

 Nadia Hassounah

Nadia Hassounah

Principal Scientist, Novartis

Rakesh Dixit

Rakesh Dixit

CEO, Bionavigen

Roy Baynes

Roy Baynes

Executive Vice President, Chief Medical Officer, Eikon Therapeutics

Nindhana Paranthaman

Nindhana Paranthaman

Principal Medical Director Oncology, Genentech

Matt Davis

Matt Davis

Director, Molecular Biology & Sequencing, Gritstone Oncology, Inc.

SPONSORS

Sanyou Bio
Proteome Sciences
Larvol
EpigenDx
Veracyte
BIOCYTOGEN
TransCure bioServices
QIAGEN
Q2 Solutions
Cureline
Biointron
StackWave
HTG Molecular Diagnostics, Inc.
Concept Lifesciences
Talem Therapeutics

PARTNERS

LOCATION

Venue

Hilton Boston Logan Airport

PAST EVENT GALLERY